These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Pang RW; Poon RT Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180 [TBL] [Abstract][Full Text] [Related]
5. Signaling pathways in hepatocellular carcinoma. Sia D; Villanueva A Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931 [TBL] [Abstract][Full Text] [Related]
6. Latest developments in targeted therapy for hepatocellular carcinoma. Montella L; Addeo R; Caraglia M; Del Prete S Expert Rev Anticancer Ther; 2010 Oct; 10(10):1635-46. PubMed ID: 20942634 [TBL] [Abstract][Full Text] [Related]
9. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Kudo M Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020 [TBL] [Abstract][Full Text] [Related]
10. The role of tyrosine kinase inhibitors in hepatocellular carcinoma. Kim S; Abou-Alfa GK Clin Adv Hematol Oncol; 2014 Jan; 12(1):36-41. PubMed ID: 25000314 [TBL] [Abstract][Full Text] [Related]
11. [Hepatocellular carcinoma]. Kondo S; Ueno H; Morizane C; Okusaka T Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702 [TBL] [Abstract][Full Text] [Related]
12. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Zhu AX Ann Surg Oncol; 2010 May; 17(5):1247-56. PubMed ID: 20405329 [TBL] [Abstract][Full Text] [Related]
13. Molecular targeted therapy for hepatocellular carcinoma: current and future. Shin JW; Chung YH World J Gastroenterol; 2013 Oct; 19(37):6144-55. PubMed ID: 24115810 [TBL] [Abstract][Full Text] [Related]
14. Pathways and targets in hepatocellular carcinoma. Psyrri A; Arkadopoulos N; Vassilakopoulou M; Smyrniotis V; Dimitriadis G Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622 [TBL] [Abstract][Full Text] [Related]
15. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Frau M; Biasi F; Feo F; Pascale RM Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048 [TBL] [Abstract][Full Text] [Related]
16. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Kudo M Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017 [TBL] [Abstract][Full Text] [Related]
17. Targeted therapy of hepatocellular carcinoma: present and future. Chan SL; Yeo W J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685 [TBL] [Abstract][Full Text] [Related]
18. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Zender L; Kubicka S Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656 [TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. Weintraub JL; Salem R J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168 [TBL] [Abstract][Full Text] [Related]
20. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Kudo M; Ueshima K Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]